data showing greater efficacy with DOACs compared with LMWHs, but cautioned about an increased risk of bleeding in patients with genitourinary tract pathology or nephrostomy tubes, or in patients with active gastrointestinal mucosal abnormalities such
Search Results
Gerald A. Soff
NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021
Featured Updates to the NCCN Guidelines
Susan M. Swetter, John A. Thompson, Mark R. Albertini, Christopher A. Barker, Joel Baumgartner, Genevieve Boland, Bartosz Chmielowski, Dominick DiMaio, Alison Durham, Ryan C. Fields, Martin D. Fleming, Anjela Galan, Brian Gastman, Kenneth Grossmann, Samantha Guild, Ashley Holder, Douglas Johnson, Richard W. Joseph, Giorgos Karakousis, Kari Kendra, Julie R. Lange, Ryan Lanning, Kim Margolin, Anthony J. Olszanski, Patrick A. Ott, Merrick I. Ross, April K. Salama, Rohit Sharma, Joseph Skitzki, Jeffrey Sosman, Evan Wuthrick, Nicole R. McMillian, and Anita M. Engh
of regional or distant metastatic disease if present. For patients with resected stage III–IV melanoma, adjuvant systemic immune and targeted therapies are an important means of improving disease-free survival. Revisions to Pathology
Thomas B. Nealis, Kay Washington, and Rajesh N. Keswani
dysplastic Barrett's. Because esophagectomy may be associated with significant morbidity, endoscopic therapies for premalignant Barrett's esophagus and early EAC have been developed and studied. Pathology of Barrett's Esophagus With the emergence of new
Matthew H. Kulke, Al B. Benson III, Emily Bergsland, Jordan D. Berlin, Lawrence S. Blaszkowsky, Michael A. Choti, Orlo H. Clark, Gerard M. Doherty, James Eason, Lyska Emerson, Paul F. Engstrom, Whitney S. Goldner, Martin J. Heslin, Fouad Kandeel, Pamela L. Kunz, Boris W. Kuvshinoff II, Jeffrey F. Moley, Venu G. Pillarisetty, Leonard Saltz, David E. Schteingart, Manisha H. Shah, Stephen Shibata, Jonathan R. Strosberg, Jean-Nicolas Vauthey, Rebekah White, James C. Yao, Deborah A. Freedman-Cass, and Mary A. Dwyer
only 19.5%. 22 In addition to information on histologic classification and stage, the margin status (positive or negative) and the presence of vascular or perineural invasion should be indicated on the pathology report, because they may also have
Christopher K. Bichakjian, Thomas Olencki, Murad Alam, James S. Andersen, Daniel Berg, Glen M. Bowen, Richard T. Cheney, Gregory A. Daniels, L. Frank Glass, Roy C. Grekin, Kenneth Grossman, Alan L. Ho, Karl D. Lewis, Daniel D. Lydiatt, William H. Morrison, Kishwer S. Nehal, Kelly C. Nelson, Paul Nghiem, Clifford S. Perlis, Ashok R. Shaha, Wade L. Thorstad, Malika Tuli, Marshall M. Urist, Timothy S. Wang, Andrew E. Werchniak, Sandra L. Wong, John A. Zic, Nicole McMillian, Karin Hoffman, and Maria Ho
during the initial development of this guideline. The latest full guideline, including a complete list of updates, is available on the NCCN Web site at NCCN.org . These NCCN Guidelines Insights highlight the addition of the “Principles of Pathology
Julie E.M. Swillens, Quirinus J.M. Voorham, Iris D. Nagtegaal, and Rosella P.M.G. Hermens
information is mainly provided by pathologists and radiologists. 4 Research has shown that inadequate pathology and radiology information can cause MDT decision failures. 5 , 6 Traditionally, diagnostic findings were reported with narrative reporting (NR
Brook Blackmore, Nicole Centers, and Troy Gifford
process. Methods: A patient identification software application (patient ID), utilizing natural language processing technology, was developed to identify positive pathology reports across the enterprise in real time. Patient ID instantly routes those
NCCN Guidelines® Insights: Breast Cancer, Version 4.2021
Featured Updates to the NCCN Guidelines
William J. Gradishar, Meena S. Moran, Jame Abraham, Rebecca Aft, Doreen Agnese, Kimberly H. Allison, Sarah L. Blair, Harold J. Burstein, Chau Dang, Anthony D. Elias, Sharon H. Giordano, Matthew P. Goetz, Lori J. Goldstein, Sara A. Hurvitz, Steven J. Isakoff, Rachel C. Jankowitz, Sara H. Javid, Jairam Krishnamurthy, Marilyn Leitch, Janice Lyons, Jennifer Matro, Ingrid A. Mayer, Joanne Mortimer, Ruth M. O'Regan, Sameer A. Patel, Lori J. Pierce, Hope S. Rugo, Amy Sitapati, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, Erica M. Stringer-Reasor, Melinda L. Telli, John H. Ward, Kari B. Wisinski, Jessica S. Young, Jennifer L. Burns, and Rashmi Kumar
developed by a multidisciplinary panel of representatives from NCCN Member Institutions with breast cancer–focused expertise in the fields of medical oncology, surgical oncology, radiation oncology, pathology, reconstructive surgery, and patient advocacy
Harry S. Cooper
intestines . In: Atlas of Tumor Pathology , 3rd Series . Washington, DC : Armed Forces Institute of Pathology ; 2003 . 2. Cooper HS . Intestinal neoplasms . In: Mills SE, Carter D, Greenson JK, et al., eds. Sternberg's Diagnostic
Jeremy S. Abramson
compared with placebo (57% vs 19%) and anemia (61% vs 0%). “Interestingly, this benefit was observed exclusively in patients with the plasmacytic or mixed histologic variants; no patients with hyaline vascular pathology responded to this regimen,” he said
